These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 1389913)
1. Alkylating agents. Connors TA Cancer Chemother Biol Response Modif; 1992; 13():31-44. PubMed ID: 1389913 [No Abstract] [Full Text] [Related]
2. Alkylating agents. Connors TA Cancer Chemother Biol Response Modif; 1990; 11():29-44. PubMed ID: 2223396 [No Abstract] [Full Text] [Related]
3. Alkylating agents, nitrosoureas and alkyltriazenes. Connors TA Cancer Chemother Biol Response Modif; 1988; 10():23-32. PubMed ID: 3079385 [No Abstract] [Full Text] [Related]
4. Alkylating agents. Connors TA Cancer Chemother Biol Response Modif; 1991; 12():27-42. PubMed ID: 1931447 [No Abstract] [Full Text] [Related]
5. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096 [TBL] [Abstract][Full Text] [Related]
6. Preclinical studies and clinical correlation of the effect of alkylating dose. Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059 [TBL] [Abstract][Full Text] [Related]
7. Alkylating agents, nitrosoureas and alkyltriazenes. Connors TA Cancer Chemother Biol Response Modif; 1987; 9():23-35. PubMed ID: 3079405 [No Abstract] [Full Text] [Related]
8. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance. Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968 [TBL] [Abstract][Full Text] [Related]
9. [Clinical pharmacology of anticancer agents. (Part 1) Introduction, alkylating agents and platinum compounds]. Fujita H Gan To Kagaku Ryoho; 1991 Nov; 18(14):2481-7. PubMed ID: 1952967 [TBL] [Abstract][Full Text] [Related]
10. [Effect of cyclophosphamide and other homologous oxazaphosphorine-2-oxides on transplantation-immunologic reactions]. Müller-Ruchholtz W Arzneimittelforschung; 1974 Aug; 24(8):1160-7. PubMed ID: 4370872 [No Abstract] [Full Text] [Related]
11. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy--a review. Waxman DJ Cancer Res; 1990 Oct; 50(20):6449-54. PubMed ID: 2208103 [No Abstract] [Full Text] [Related]
12. Alkylating agents. Berger NA Cancer Chemother Biol Response Modif; 1994; 15():32-43. PubMed ID: 7779588 [No Abstract] [Full Text] [Related]
13. [Repair of DNA-protein cross-links induced by antineoplastic alkylating agents]. Lomova TIu; Shakhova IK; Shkodinskaia EN Biull Eksp Biol Med; 1981 Jul; 92(7):74-6. PubMed ID: 7295949 [TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance is a component of V79 cell resistance to the alkylating agent adozelesin. Bhuyan BK; Smith KS; Kelly RC; Adams EG; Abraham I; Sampson KE Cancer Res; 1993 Mar; 53(6):1354-9. PubMed ID: 8443816 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo. Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913 [TBL] [Abstract][Full Text] [Related]
16. The biology of alkylating-agent cellular injury. Shulman LN Hematol Oncol Clin North Am; 1993 Apr; 7(2):325-35. PubMed ID: 8468267 [TBL] [Abstract][Full Text] [Related]
17. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813 [TBL] [Abstract][Full Text] [Related]